Abstract: Sorafenib (BAY 43-9006) is a pioneering multi-kinase inhibitor that established the paradigm for systemic targeted therapy in advanced hepatocellular carcinoma (HCC). While it provides survival benefits by inhibiting angiogenesis and tumor cell proliferation, its long-term clinical efficacy is significantly hindered by poor pharmacokinetics, dose-limiting toxicities, and the rapid emergence of drug resistance. Recent research has increasingly focused on tumor combination immunotherapy to overcome these barriers. Sorafenib exhibits intrinsic immunomodulatory properties, such as reprogramming tumor-associated macrophages and reducing immunosuppressive cells, which synergize with immune checkpoint inhibitors (ICIs). Furthermore, advanced nanotechnology-based drug delivery systems (NDDS) are being developed to co-deliver sorafenib and immunotherapeutic agents, enhancing tumor-specific accumulation and reversing the immunosuppressive tumor microenvironment (TME). This review explores the pharmacological mechanisms, limitations, and future perspectives of sorafenib, emphasizing its integration with immunotherapy and nanomedicine.
1. Introduction
Sorafenib (BAY 43-9006) is an oral, multi-target tyrosine kinase inhibitor (TKI) that serves as a cornerstone first-line systemic therapy for advanced hepatocellular carcinoma (HCC) [4][8]. By simultaneously targeting tumor cell proliferation and tumor angiogenesis, sorafenib has been shown to extend median overall survival and time to radiologic progression in patients with advanced HCC [4][8]. Despite its clinical success, the therapeutic potential of sorafenib is constrained by significant limitations. Only a fraction of patients achieve long-term benefits due to the rapid onset of acquired resistance—typically within six months—and severe dose-limiting toxicities [4]. To address these challenges, the research landscape has shifted toward combination strategies, particularly tumor combination immunotherapy. The rationale is based on the non-overlapping toxicity profiles of TKIs and immune checkpoint inhibitors (ICIs), as well as the synergistic potential of combining anti-angiogenesis with immune activation to overcome the highly immunosuppressive nature of HCC [7].
2. Pharmacological Activity
Sorafenib exhibits broad-spectrum antitumor activity primarily through anti-angiogenic and anti-proliferative pathways [1][2]. Beyond direct cytotoxicity, sorafenib profoundly modulates the tumor microenvironment (TME) and the host immune system. It reduces the abundance and activity of immunosuppressive populations such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) [1][10]. A key pharmacological activity is its ability to redirect tumor-associated macrophage (TAM) polarization from the pro-tumorigenic M2 state to the pro-inflammatory M1 state, thereby enhancing the infiltration and effector function of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells [1]. Additionally, sorafenib indirectly improves the structural properties of the extracellular matrix (ECM) by inhibiting TGF-β-mediated cancer-associated fibroblast (CAF) activation, reducing ECM stiffness, and facilitating improved drug diffusion within the tumor tissue [1].
3. Molecular Mechanism of Action
At the molecular level, sorafenib targets multiple receptor tyrosine kinases (RTKs) and intracellular signaling cascades. It inhibits the Raf/MEK/ERK signaling pathway by binding to Raf kinase, preventing downstream activation of MEK and ERK, and thereby suppressing tumor cell proliferation [1][4]. For anti-angiogenesis, sorafenib blocks VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β, FGFR, and c-KIT, which disrupts endothelial cell proliferation, migration, and pericyte recruitment [1][4][8]. Furthermore, sorafenib suppresses the accumulation of hypoxia-inducible factor-1 alpha (HIF-1α), limiting VEGF transcription [1]. It also modulates the PI3K/Akt/mTOR pathway, inducing autophagy-dependent cell death, and downregulates cyclin-dependent kinases (CDKs) to cause cell cycle arrest at the G1 phase [1]. Importantly for immunotherapy, sorafenib indirectly reduces programmed death-ligand 1 (PD-L1) expression on tumor cells, likely through the inhibition of TGF-β signaling, which sensitizes tumors to anti-PD-1/PD-L1 therapies [1].
4. Structure-Activity Relationship (SAR) and Nano-Bio Interactions
The physical and chemical structure of sorafenib is highly hydrophobic, resulting in poor aqueous solubility, rapid systemic clearance, and low bioavailability, which necessitates high oral dosing regimens [1]. To optimize its structure-activity profile and overcome these pharmacokinetic barriers, various nanotechnology-based drug delivery systems (NDDS) have been engineered. Lipid-based nanocarriers, polymeric micelles, and glycoconjugated nanoparticles (e.g., using lactobionic acid to target the ASGPR receptor on HCC cells) significantly enhance its solubility and tumor-specific accumulation [1][5]. Stimuli-responsive platforms exploit the acidic, hypoxic, and redox-imbalanced TME to trigger localized sorafenib release. These nano-bio interactions maximize kinase inhibition at the tumor site while minimizing off-target systemic exposure, effectively bridging the gap between the drug's molecular potency and its clinical delivery [1][5].
5. Current Limitations
The clinical utility of sorafenib is constrained by several critical factors. First, its poor pharmacokinetic profile requires high dosing, leading to dose-limiting toxicities such as hand-foot skin reactions, diarrhea, hypertension, and gastrointestinal bleeding [1][4][5]. Second, acquired resistance rapidly emerges through multiple adaptive mechanisms. Tumor cells adapt by activating compensatory oncogenic pathways (e.g., c-Met, STAT3, PI3K/Akt/mTOR) and undergoing epithelial-mesenchymal transition (EMT) [1][4]. Epigenetic biological processes and noncoding RNAs (miRNAs and lncRNAs) also play a crucial role in mediating sorafenib resistance [3][4]. Metabolic reprogramming further drives resistance; enhanced glycolysis and excessive lactate extrusion by sorafenib-resistant HCC cells create an acidic TME that suppresses CD8+ T cells and upregulates PD-1 on Tregs, fostering immune evasion [9]. Additionally, hypoxia induced by sorafenib's anti-angiogenic effect can paradoxically promote tumor stemness and upregulate drug efflux transporters like ABCG2 [1].
6. Future Perspectives
The future of sorafenib therapy lies in the integration of combination immunotherapy and advanced nanomedicine. Combining sorafenib with ICIs (e.g., nivolumab, pembrolizumab, camrelizumab) has shown promising synergistic effects in clinical trials, as anti-angiogenesis normalizes tumor vasculature and enhances T-cell infiltration, while ICIs reverse immune exhaustion [2][6][7]. To mitigate the overlapping toxicities of systemic combinations, co-delivery nanoplatforms are being developed. Biomimetic nanoparticles (such as platelet or cancer cell membrane-coated NPs) and hydrogels are being utilized to co-deliver sorafenib with PD-L1 siRNA or anti-PD-1 antibodies, achieving precise TME reprogramming and robust anti-tumor immunity [1][5]. Furthermore, the integration of artificial intelligence (AI) and machine learning is revolutionizing the design of these nanocarriers, enabling high-throughput screening for optimal drug-excipient pairings and paving the way for personalized, precision nanomedicine in HCC [1].
